These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

252 related articles for article (PubMed ID: 39167893)

  • 1. Structural insights into small-molecule KRAS inhibitors for targeting KRAS mutant cancers.
    Pandey D; Chauhan SC; Kashyap VK; Roy KK
    Eur J Med Chem; 2024 Nov; 277():116771. PubMed ID: 39167893
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeting mutated GTPase KRAS in tumor therapies.
    Fan G; Lou L; Song Z; Zhang X; Xiong XF
    Eur J Med Chem; 2021 Dec; 226():113816. PubMed ID: 34520956
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Activity and resistance to KRAS
    Ye W; Lu X; Qiao Y; Ou WB
    Biochim Biophys Acta Rev Cancer; 2024 May; 1879(3):189108. PubMed ID: 38723697
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Beyond KRAS(G12C): Biochemical and Computational Characterization of Sotorasib and Adagrasib Binding Specificity and the Critical Role of H95 and Y96.
    Mahran R; Kapp JN; Valtonen S; Champagne A; Ning J; Gillette W; Stephen AG; Hao F; Plückthun A; Härmä H; Pantsar T; Kopra K
    ACS Chem Biol; 2024 Oct; 19(10):2152-2164. PubMed ID: 39283696
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeting KRAS Diversity: Covalent Modulation of G12X and Beyond in Cancer Therapy.
    Kirschner T; Müller MP; Rauh D
    J Med Chem; 2024 Apr; 67(8):6044-6051. PubMed ID: 38621359
    [TBL] [Abstract][Full Text] [Related]  

  • 6. From bench to bedside: current development and emerging trend of KRAS-targeted therapy.
    Chen Y; Liu QP; Xie H; Ding J
    Acta Pharmacol Sin; 2024 Apr; 45(4):686-703. PubMed ID: 38049578
    [TBL] [Abstract][Full Text] [Related]  

  • 7. KRAS mutation: from undruggable to druggable in cancer.
    Huang L; Guo Z; Wang F; Fu L
    Signal Transduct Target Ther; 2021 Nov; 6(1):386. PubMed ID: 34776511
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Targeting Kras
    Christensen JG; Olson P; Briere T; Wiel C; Bergo MO
    J Intern Med; 2020 Aug; 288(2):183-191. PubMed ID: 32176377
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Annual review of KRAS inhibitors in 2022.
    Wang H; Chi L; Yu F; Dai H; Gao C; Si X; Wang Z; Liu L; Zheng J; Shan L; Liu H; Zhang Q
    Eur J Med Chem; 2023 Mar; 249():115124. PubMed ID: 36680986
    [TBL] [Abstract][Full Text] [Related]  

  • 10. KRAS G12C Game of Thrones, which direct KRAS inhibitor will claim the iron throne?
    Nagasaka M; Li Y; Sukari A; Ou SI; Al-Hallak MN; Azmi AS
    Cancer Treat Rev; 2020 Mar; 84():101974. PubMed ID: 32014824
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Small-Molecule Inhibitors Directly Targeting KRAS as Anticancer Therapeutics.
    Chen H; Smaill JB; Liu T; Ding K; Lu X
    J Med Chem; 2020 Dec; 63(23):14404-14424. PubMed ID: 33225706
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Glimmers of hope for targeting oncogenic KRAS-G12D.
    Tang D; Kang R
    Cancer Gene Ther; 2023 Mar; 30(3):391-393. PubMed ID: 36414681
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targeted Therapies for Previously "Undruggable" KRAS-Mutated Non-Small Cell Lung Cancer: A Review of Sotorasib and Adagrasib.
    Mausey N; Halford Z
    Ann Pharmacother; 2024 Jun; 58(6):622-635. PubMed ID: 37700573
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The next-generation KRAS inhibitors…What comes after sotorasib and adagrasib?
    Oya Y; Imaizumi K; Mitsudomi T
    Lung Cancer; 2024 Aug; 194():107886. PubMed ID: 39047616
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Research progress on small molecule inhibitors targeting KRAS G12C with acrylamide structure and the strategies for solving KRAS inhibitor resistance.
    Jiang Z; Li Y; Zhou X; Wen J; Zheng P; Zhu W
    Bioorg Med Chem; 2024 Feb; 100():117627. PubMed ID: 38310752
    [TBL] [Abstract][Full Text] [Related]  

  • 16. KRAS: From undruggable to a druggable Cancer Target.
    Uprety D; Adjei AA
    Cancer Treat Rev; 2020 Sep; 89():102070. PubMed ID: 32711246
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Targeting KRAS
    Torres-Jiménez J; Espinar JB; de Cabo HB; Berjaga MZ; Esteban-Villarrubia J; Fraile JZ; Paz-Ares L
    Drugs; 2024 May; 84(5):527-548. PubMed ID: 38625662
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inhibition of RAS: proven and potential vulnerabilities.
    Zuberi M; Khan I; O'Bryan JP
    Biochem Soc Trans; 2020 Oct; 48(5):1831-1841. PubMed ID: 32869838
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical Acquired Resistance to KRAS
    Tanaka N; Lin JJ; Li C; Ryan MB; Zhang J; Kiedrowski LA; Michel AG; Syed MU; Fella KA; Sakhi M; Baiev I; Juric D; Gainor JF; Klempner SJ; Lennerz JK; Siravegna G; Bar-Peled L; Hata AN; Heist RS; Corcoran RB
    Cancer Discov; 2021 Aug; 11(8):1913-1922. PubMed ID: 33824136
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Recent progress in targeting KRAS mutant cancers with covalent G12C-specific inhibitors.
    Rathod LS; Dabhade PS; Mokale SN
    Drug Discov Today; 2023 May; 28(5):103557. PubMed ID: 36934967
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.